Skip to content

Intensive endoscopic therapy versus standard treatment for untreated benign esophageal strictures resulting from excessive scar tissue formation after surgery

Intensive endoscopic therapy versus conventional treatment for untreated benign anastomotic strictures after esophagectomy: a pilot and randomized controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON29569
Enrollment
89
Registered
2016-02-29
Start date
2016-09-01
Completion date
Unknown
Last updated
2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign esophageal strictures

Interventions

Intensive endoscopic therapy (=investigational treatment): a) Endoscopic in- and excision of the stenotic fibrotic ring using a needle knife catheter. b) Followed by injection of 0.5 ml aliquots Ken

Sponsors

Academic Medical Center
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: - Untreated benign esophagogastric anastomotic stricture after esophagectomy. - The stricture should be suitable for endoscopic incision: a) Diagnosed at least 6 weeks after esophagectomy, and b) Stricture length ≤ 1 cm. - Dysphagia score ≥ 2. - Age > 18 years. - Written informed consent for study participation.

Exclusion criteria

Exclusion criteria: - Benign esophageal stricture other than an esophagogastric anastomotic stricture. - Strictures with a morphology unsuitable for needle-knife incision, such as long (> 1 cm), irregulair or tortuous strictures. - Previous endoscopic treatment of the esophageal stricture, such as bougie/balloon dilation, steroid injection, incision therapy or stent placement. - Previous stent placement post-esophagectomy for anastomotic leakage. - (Suspicion of) recurrent or metastasized esophageal cancer. - Persisting postoperative esophageal fistula. - Inability to discontinue anticoagulants or high-dose antiplatelet drugs at time of the baseline procedure. Low-dose aspirin (max. 100 mg/day) may be continued. - Known clotting disorder. - Patients unable to provide written consent for the study.

Design outcomes

Primary

MeasureTime frame
Dysphagia-free period

Secondary

MeasureTime frame
Number of endoscopic dilations, technical success, procedure-related complications, dysphagia scores and therapy satisfaction score.

Contacts

Public ContactE.E. Halsema, van

-

e.e.halsemavan@amc.nl+31(0)205668708

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)